Repository logo
 
No Thumbnail Available
Publication

Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results

Use this identifier to reference this record.
Name:Description:Size:Format: 
ART_Ana_Rita_Santos_5.pdf931.61 KBAdobe PDF Download

Advisor(s)

Abstract(s)

The beneficial effect of an early switch to DEX implant in DME non-responders seen at month 12 was main- tained during the second year. A later switch from anti-VEGF to steroids still provided significant improvement. Eyes continued on anti-VEGF over a period of 24 months maintained vision. A quarter of eyes, which had not improved vision at 12 months, exhibited a delayed response to treatment.

Description

Keywords

Refractory diabetic macular edema Anti-VEGF therapy Dexamethasone implant Intravitreal therapy Long- term outcome

Citation

Busch, C., Fraser-Bell, S., Iglicki, M. et al. Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results. Acta Diabetol 56, 1341–1350 (2019). https://doi.org/10.1007/s00592-019-01416-4

Research Projects

Organizational Units

Journal Issue

Publisher

Springer

CC License

Altmetrics